Skip to main content

Table 2 Rates of control for secondary prevention measures by study group

From: Can cardiovascular risk management be improved by shared care with general practice to prevent cognitive decline following stroke/TIA? A feasibility randomised controlled trial (SERVED memory)

  Observation (N = 71) Control (N = 22) Intervention (N = 16)
Baseline 12 months Baseline 12 months Baseline 12 months
Antiplatelet use 50/71 (70.4%) 51/71 (71.8%) 17/22 (77.3%) 15/22 (68.2%) 10/16 (62.5%) 10/16 (62.5%)
Systolic BP (mmHg) 147.8 (21.2) 152.1 (18.1) 148.3 (20.3) 152.4 (23.3) 143.7 (14.2) 156.1 (19.4)
Diastolic BP (mmHg) 80.3 (10.4) 84.5 (10.9) 80.2 (10.8) 81.1 (14.3) 82.7 (10.0) 88.9 (12.5)
BP < 130/80 mmHg 7/71 (9.9%) 2/71 (2.8%) 2/22 (9.1%) 1/22 (4.5%) 2/16 (12.5%) 0/16 (0.0%)
BP < 140/90 mmHg 24/71 (33.8%) 19/71 (26.8%) 7/22 (31.8%) 5/22 (22.7%) 6/16 (37.5%) 2/16 (12.5%)
Total Cholesterol (mmol/L) 4.9 (1.1) 4.4 (1.0) 4.9 (1.0) 4.3 (1.0) 4.1 (0.8) 3.9 (1.0)
Total Cholesterol < 4.0 mmol/L 16/71 (22.5%) 28/71 (39.4%) 4/22 (18.2%) 10/22 (45.5%) 8/16 (50.0%) 10/16 (62.5%)
Heart rate (beats per min)a, 75.7 (12.1) 74.5 (12.3) 68.4 (13.8) 72.3 (18.9) 78.3 (5.5) 71.1 (10.5)
HR 60-80 bpma 10/21 (47.6%) 12/23 (52.2%) 2/3 (66.7%) 2/6 (33.3%) 3/5 (60.0%) 5/7 (71.4%)
Adequate anticoagulationa,b 8/21 (38.1%) 18/23 (78.3%) 3/3 (100.0%) 5/6 (83.3%) 1/5 (20.0%) 6/7 (85.7%)
HbA1C mmol/molc 51.0 (44.3, 64.3) 49.0 (44.0, 69.3) 80.0 (−) 66.0 (−) 53.5 (−) 62.0 (−)
HbA1C 48-53 mmol/molc 5/15 (33.3%) 4/17 (23.5%) 0/3 (0.0%) 0/3 (0.0%) 1/2 (50.0%) 1/3 (33.3%)
  1. Average values and rates of control for secondary vascular prevention measures at baseline and 12 months by study group (restricted to participants who completed follow-up). Data presented are mean (SD), median (IQR), or frequency (%)
  2. aOnly those with AF
  3. bINR 2.5–3.0 or on a DOAC
  4. cOnly those with diabetes